Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Jing Deng, PhD, Yan Yin, MS, Tingting Mao, MS, Guoqin Zhai, MS, Dongmei Yang, MS, Douglas Fang, MD PhD, Shaomeng Wang, PhD, Yifan Zhai, MD PhD, Dajun Yang, MD PhD

Blood (2018) 132 (Supplement 1): 2616.

https://doi.org/10.1182/blood-2018-99-119816

Published: 2018

Journal Articles

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Misbah Sabir, MSc, Monica Hellesoy, PhD, Jarno Kivioja, MSc, Caroline Engen, MD, Claire Amiable, Mihaela Popa, Remi Guillon, Øystein Bruserud, MD PhD, Caroline A Heckman, PhD, Emmet McCormack, BSc, PhD, Dominique Surleraux, Bjørn Tore Gjertsen

Blood (2017) 130 (Supplement 1): 3349.

https://doi.org/10.1182/blood.V130.Suppl_1.3349.3349

Published: 2017

Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 717.

https://doi.org/10.1182/blood.V130.Suppl_1.717.717

Published: 2017

Journal Articles

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD PhD, Rachel Astles, BA, Alexis Zebrowski, BA, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2016) 128 (22): 755.

https://doi.org/10.1182/blood.V128.22.755.755

Published: 2016

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Oliver Herrmann, Msc, Claudia Schubert, Msc, Tom Luedde, MD PhD, Till Braunschweig, MD, Steffen Koschmieder, MD, Tim H Brümmendorf, MD, Mirle Schemionek, PhD

Blood (2015) 126 (23): 15.

https://doi.org/10.1182/blood.V126.23.15.15

Published: 2015

Journal Articles

Overexpression of the Metabolic Stress Sensor and Proglycolytic Transcription Factor ΜLΧΙΡ Mediates Malignancy of Common Acute Lymphoblastic Leukemia in Vivo and Is Targetable By Allorestricted Peptide Specific T Cells

Alexandra Sipol, Thomas Grünewald, Guenther Richter, Caroline Wernicke, Hans-Jochem Kolb, Torsten Haferlach, Stefan Burdach

Blood (2014) 124 (21): 2436.

https://doi.org/10.1182/blood.V124.21.2436.2436

Published: 2014

Journal Articles

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Mayumi Sugita, MD, Grace R Jeschke, Martin P. Carroll, MD, Alexander E. Perl, MD

Blood (2014) 124 (21): 2371.

https://doi.org/10.1182/blood.V124.21.2371.2371

Published: 2014

Journal Articles

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

Oliver Herrmann, MSc, Caroline CA Weßling, MD, Michael Huber, PhD, Shaoguang Li, MD PhD, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Mirle Schemionek, PhD

Blood (2014) 124 (21): 4528.

https://doi.org/10.1182/blood.V124.21.4528.4528

Published: 2014

Journal Articles

STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia

Maurizio Mangolini, Jasper de Boer, Vanessa Walf-Vorderwülbecke, Rob Pieters, Monique L. den Boer, Owen Williams

Blood (2013) 122 (4): 542–549.

https://doi.org/10.1182/blood-2012-11-465252

Published: 2013

Includes: Supplemental data

Journal Articles

Receptor Tyrosine Kinases, Notch Mutations and PTEN Loss Converge On mTOR in T-ALL and Cause Addiction to Cap Dependent mRNA Translation.

Adrian Schwarzer, MD, Helmut Holtmann, PhD, Martijn Brugman, PhD, Johann Meyer, PhD, Doris Steinemann, PhD, Brigitte Schlegelberger, Zhixiong Li, MD, Christopher Baum, MD

Blood (2012) 120 (21): 2415.

https://doi.org/10.1182/blood.V120.21.2415.2415

Published: 2012

Journal Articles

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Mirle Schemionek, PhD, Ulrich Steidl, MD, PhD, Albrecht Schwab, MD, Daniel G Tenen, MD, Copland Mhairi, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Christian Preisinger, PhD, Carsten Mueller-Tidow, MD, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 2776.

https://doi.org/10.1182/blood.V120.21.2776.2776

Published: 2012

Journal Articles

Crosstalk Between Cyclins D1 and D3 in Mantle Cell Level At the Transcriptional and Postranscriptional Levels

August Stuart, BA, Sara Shimko, BA, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 1373.

https://doi.org/10.1182/blood.V118.21.1373.1373

Published: 2011

Journal Articles

Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas

Roland Schmitz, PhD, Sameer Jhavar, MD, Wenming Xiao, PhD, Xuelu Liu, John Powell, George W. Wright, Wing C. Chan, MD, Elaine S. Jaffe, MD, Randy D. Gascoyne, MD, Elias Campo, MD, Andreas Rosenwald, MD, German Ott, MD, Jan Delabie, MD, PhD, Lisa M. Rimsza, MD, Louis M. Staudt, MD, PhD

Blood (2011) 118 (21): 435.

https://doi.org/10.1182/blood.V118.21.435.435

Published: 2011

Journal Articles

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

Joanna Zabkiewicz, PhD, Lorna Pearn, Robert Hills, MA, MSc, DPhil, Rhys, Gareth Morgan, BSc, Alan Burnett, MD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2010) 116 (21): 2162.

https://doi.org/10.1182/blood.V116.21.2162.2162

Published: 2010

Journal Articles

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Caroline Ho, MS, Rachel Rice, BS, Denis Drygin, PhD, Josh Bliesath, BS, Nicole Streiner, BS, Adam Siddiqui-Jain, PhD, Chris Proffitt, BS, Sean O'Brien, PhD, Kenna Anderes, PhD

Blood (2010) 116 (21): 787.

https://doi.org/10.1182/blood.V116.21.787.787

Published: 2010

Journal Articles

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Lauren I Aronson, Emma L Davenport, Serena G Giuntoli, Muralikrishnan Srikanth, Emma Smith, Gareth J Morgan, MD, PhD, Faith Davies

Blood (2010) 116 (21): 4083.

https://doi.org/10.1182/blood.V116.21.4083.4083

Published: 2010

Journal Articles

High Levels of the Adhesion Molecule CD44 on Leukemic Cells Generate Acute Myeloid Leukemia Relapse After Withdrawal of the Initial Transforming Event

Ronan Quere, PhD, Silja Andradottir, Ann Brun, PhD, Roman Zubarev, PhD, Göran Karlsson, PhD, Karin Olsson, Mattias Magnusson, PhD, Jörg Cammenga, MD, PhD, Stefan Karlsson, MD, PhD

Blood (2010) 116 (21): 3154.

https://doi.org/10.1182/blood.V116.21.3154.3154

Published: 2010

Journal Articles

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Zohar Sachs, MD, PhD, Ernesto Diaz-Flores, PhD, Miechaleen D Diers, Karen Sachs, Sean C Bendall, PhD, Harris G Fienberg, Susan K Rathe, Garry P. Nolan, Ph.D., Kevin Shannon, MD, David Largaespada, PhD

Blood (2010) 116 (21): 3160.

https://doi.org/10.1182/blood.V116.21.3160.3160

Published: 2010

NARROW

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Overexpression of the Metabolic Stress Sensor and Proglycolytic Transcription Factor ΜLΧΙΡ Mediates Malignancy of Common Acute Lymphoblastic Leukemia in Vivo and Is Targetable By Allorestricted Peptide Specific T Cells

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia

Receptor Tyrosine Kinases, Notch Mutations and PTEN Loss Converge On mTOR in T-ALL and Cause Addiction to Cap Dependent mRNA Translation.

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Crosstalk Between Cyclins D1 and D3 in Mantle Cell Level At the Transcriptional and Postranscriptional Levels

Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

High Levels of the Adhesion Molecule CD44 on Leukemic Cells Generate Acute Myeloid Leukemia Relapse After Withdrawal of the Initial Transforming Event

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only